SIEMENS HEALTHINEERS AG

European markets dip as Middle East tensions rise and tech pulls back, but Siemens Healthineers steadies with strong Q1 revenue, a widening margin, and new AI‑driven MRI partnership. Explore how its quantitative imaging edge could boost oncology dia…

Siemens Healthineers renews its partnership with Imagion Biosystems to boost HER2 breast‑cancer imaging, aiming for higher safety and quality with lower contrast doses and AI‑driven diagnostics.

Siemens Healthineers leads oncology pre‑clinical research, delivering advanced imaging, PK/PD, biomarker, and toxicology services that speed cancer drug development and improve patient outcomes.

Siemens Healthineers leads the Fourth China International Supply Chain Expo, showcasing AI‑powered diagnostics, local manufacturing, and market‑stable tech that boosts global healthcare innovation.

Siemens Healthineers boosts share‑buyback to 1.4 M shares, aiming to lift its 23 % price drop while driving AI‑enabled cardiology and oncology diagnostics.

Siemens Healthineers expands precision‑medicine with a €200 m Dunstable radiopharmaceutical plant and MindShift Alzheimer’s alignment, boosting PET/CT throughput, job creation, and EU diagnostic growth potential.

Siemens Healthineers faces a market dip and a major UPC injunction, exposing legal, reimbursement, and supply‑chain risks—yet strong margins and AI investment keep long‑term growth in focus.

Siemens Healthineers shares rise modestly, but a UPC patent injunction and supply‑chain hurdles threaten 18‑month sales. Explore how AI, edge computing, and new partnerships keep the firm ahead in digital‑health innovation while managing IP risk and…

Siemens Healthineers shares dip 1% in June 2024, reflecting mild market volatility. Still, robust regulatory compliance, AI innovation, and proven imaging quality keep the company a trusted medical‑device leader.

Siemens Healthineers shares dip 0.9% as a 12‑month decline hits 8.4%. The buyback hints at confidence, but margin pressure and rising costs risk further erosion—investors eye AI diagnostics and regulatory impacts for recovery.